Cutera (Cutera) Debt-to-Equity

: -3.71 (As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

Cutera's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.5 Mil. Cutera's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $427.6 Mil. Cutera's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-116.1 Mil. Cutera's debt to equity for the quarter that ended in Sep. 2023 was -3.71.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cutera's Debt-to-Equity or its related term are showing as below:

CUTR' s Debt-to-Equity Range Over the Past 10 Years
Min: -28.37 Med: 0.29 Max: 20.35
Current: -3.71

During the past 13 years, the highest Debt-to-Equity Ratio of Cutera was 20.35. The lowest was -28.37. And the median was 0.29.

CUTR's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs CUTR: -3.71

Cutera Debt-to-Equity Historical Data

The historical data trend for Cutera's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.17

0.45

2.65

-28.37

Cutera Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity																20.35	-28.37	-11.05	-6.24	-3.71

Competitive Comparison

For the Medical Devices subindustry, Cutera's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cutera Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Cutera's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cutera's Debt-to-Equity falls into.

Cutera Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cutera's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.81	+	427.811)	/	-15.181
	=	-28.37

Cutera's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.511	+	427.595)	/	-116.085
	=	-3.71

Cutera (NAS:CUTR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cutera Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cutera's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutera (Cutera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

TJ9:Germany

Address

3240 Bayshore Boulevard, Brisbane, CA, USA, 94005

Website

https://www.cutera.com

Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.

Executives

Taylor C. Harris	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond	officer: Interim Chief Financial Office	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones	officer: Chief Operating Officer	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan	director	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry	director, officer: Chief Executive Officer	9775 TOLEDO, IRVINE CA 92618
Rohan Seth	officer: Chief Financial Officer	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann	director	1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants	director	ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters	director
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016